1
|
Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncoimmunology 2021; 1:75-77. [PMID: 22720216 DOI: 10.4161/onci.1.1.17825] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The immune status is important in cancer patients. Tissue microarrays from 249 patients with soft tissue sarcomas were constructed. Immunohistochemistry was used to evaluate the CD3+, CD4+, CD8+, CD20+ and CD45+ lymphocytes in tumors. High density of CD20+ lymphocytes is an independent positive prognostic indicator for these patients.
Collapse
Affiliation(s)
- Sveinung W Sorbye
- Dept. of Clinical Pathology, University Hospital of North Norway; Tromso, Norway ; Institute of Medical Biology, University of Tromso; Tromso, Norway
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Mäkitie A, Ruuskanen M, Bentzen J, Brun E, Gebre-Medhin M, Friesland S, Marsk E, Hammarstedt-Nordenvall L, Gille E, Reizenstein J, Adell G, Farnebo L, Rzepecki J, Haugen H, Söderström K, Zackrisson B, Bergström S, Lödén B, Cederblad L, Laurell G, Smeland E, Folkvard Evensen J, Lund JÅ, Tøndel H, Karlsdottir Å, Jóhannsson J, Johansen J, Kristensen CA, Jensen K, Andersen LJ, Koivunen P, Korpela M, Voutilainen L, Wigren T, Minn H, Joensuu H, Overgaard J, Saarilahti K. The management and survival outcomes of nasopharyngeal cancer in the Nordic countries<sup/>. Acta Oncol 2018; 57:557-560. [PMID: 29202641 DOI: 10.1080/0284186x.2017.1408961] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- A. Mäkitie
- Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - M. Ruuskanen
- Department of Otorhinolaryngology – Head and Neck Surgery, Turku University Hospital, Turku, Finland
| | - J. Bentzen
- Department of Oncology, Herlev University Hospital, Copenhagen, Denmark
| | - E. Brun
- Department of Oncology, Skane University Hospital, Lund University, Sweden
| | - M. Gebre-Medhin
- Department of Oncology, Skane University Hospital, Lund University, Sweden
| | - S. Friesland
- Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
| | - E. Marsk
- Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - L. Hammarstedt-Nordenvall
- Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - E. Gille
- Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - J. Reizenstein
- Department of Oncology, Örebro University Hospital, Örebro, Sweden
| | - G. Adell
- Department of Oncology, Linköping University Hospital, Linköping, Sweden
| | - L. Farnebo
- Department of Otorhinolaryngology – Head and Neck Surgery, Linköping University Hospital, Linköping, Sweden
| | - J. Rzepecki
- Department of Oncology, Linköping University Hospital, Linköping, Sweden
| | - H. Haugen
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - K. Söderström
- Department of Radiation Sciences, Umeå University, Umeå, Sweden
| | - B. Zackrisson
- Department of Radiation Sciences, Umeå University, Umeå, Sweden
| | - S. Bergström
- Department of Oncology, Gävle Hospital, Gävle, Sweden
| | - B. Lödén
- Department of Oncology, Karlstad Hospital, Karlstad, Sweden
| | - L. Cederblad
- Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
| | - G. Laurell
- Department of Otorhinolaryngology – Head and Neck Surgery, Uppsala University Hospital, Uppsala, Sweden
| | - E. Smeland
- Department of Oncology, University Hospital North Norway, Tromsoe, Norway
| | | | - J. Å. Lund
- Department of Oncology, Trondheim University Hospital, Trondheim, Norway
| | - H. Tøndel
- Department of Oncology, Trondheim University Hospital, Trondheim, Norway
| | - Å. Karlsdottir
- Department of Oncology, Haukeland University Hospital, Bergen, Norway
| | - J. Jóhannsson
- Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland
| | - J. Johansen
- Department of Oncology, Odense University Hospital, Odense, Denmark
| | - C. A. Kristensen
- Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark
| | - K. Jensen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - L. J. Andersen
- Department of Oncology, Aalborg Hospital, Aalborg, Denmark
| | - P. Koivunen
- Department of Otorhinolaryngology – Head and Neck Surgery, Oulu University Hospital, Oulu, Finland
| | - M. Korpela
- Department of Oncology, Oulu University Hospital, Oulu, Finland
| | - L. Voutilainen
- Department of Oncology, Kuopio University Hospital, Kuopio, Finland
| | - T. Wigren
- Department of Oncology, Tampere University Hospital, Tampere, Finland
| | - H. Minn
- Department of Oncology, Turku University Hospital, Turku, Finland
| | - H. Joensuu
- Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - J. Overgaard
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - K. Saarilahti
- Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| |
Collapse
|
3
|
Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel R, Delabie J, Weisenburger D, Song J, Chan J, Cook J, Fu K, Greiner T, Smeland E, Holte H, Glinsmann-Gibson B, Gascoyne R, Staudt L, Jaffe E, Connors J, Scott D, Steidl C, Rimsza L. MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS - AN LLMPP PROJECT. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Mottok
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - G.W. Wright
- Biometric Research Branch; National Cancer Institute; Rockville USA
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - G. Ott
- Department of Pathology; Robert-Bosch-Krankenhaus; Stuttgart Germany
| | - C. Ramsower
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| | - E. Campo
- Hematopathology Unit; Hospital Clinic Barcelona; Barcelona Spain
| | - R.M. Braziel
- Department of Pathology; Oregon Health & Science University Portland; Portland USA
| | - J. Delabie
- Department of Pathology; University Health Network; Toronto Canada
| | - D.D. Weisenburger
- Department of Pathology, Hematopathology Section and Lymph Node Registry; City of Hope Medical Center; Duarte USA
| | - J.Y. Song
- Department of Pathology, Hematopathology Section and Lymph Node Registry; City of Hope Medical Center; Duarte USA
| | - J.W. Chan
- Department of Pathology, Hematopathology Section and Lymph Node Registry; City of Hope Medical Center; Duarte USA
| | - J.R. Cook
- Department of Laboratory Medicine and Pathology; Cleveland Clinic; Cleveland USA
| | - K. Fu
- Department of Pathology; University of Nebraska Medical Center; Omaha USA
| | - T. Greiner
- Department of Pathology; University of Nebraska Medical Center; Omaha USA
| | - E. Smeland
- Department of Immunology, Institute for Cancer Research; The Norwegian Radium Hospital; Oslo Norway
| | - H. Holte
- Department of Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital; Oslo University Hospital; Oslo Norway
| | - B. Glinsmann-Gibson
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - L.M. Staudt
- Center for Cancer Research, Lymphoid Malignancies Branch; National Cancer Institute; Bethesda USA
| | - E.S. Jaffe
- Hematopathology Section; National Cancer Institute; Bethesda USA
| | - J.M. Connors
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - D. Scott
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - C. Steidl
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - L.M. Rimsza
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| |
Collapse
|
4
|
Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM, Busund LT, Donnem T. The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk. BMC Clin Pathol 2014; 14:5. [PMID: 24444363 PMCID: PMC3898209 DOI: 10.1186/1472-6890-14-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2013] [Accepted: 01/16/2014] [Indexed: 12/18/2022] Open
Abstract
Background Soft-tissue sarcomas are rare malignant tumors of mesenchymal lineage that can arise in any part of the body. Prognosis, and hence also treatment may vary according to histologic subtype and localization. Angiogenesis is the process of forming new blood vessels from pre-existing ones. The deregulation of this process is thought to be an important step in malignant transformation. This study investigates the prognostic impact of platelet derived growth factor- (PDGF), vascular endothelial growth factor- (VEGF) and fibroblast growth factor (FGF) families in soft-tissue sarcomas of the extremities & trunk (ET) and visceral & retroperitoneal (VR) locations. Methods Tumor samples from 181 patients (115 ET and 66 VR) with resected soft tissue sarcomas were collected and tissue microarrays were constructed. Immunohistochemistry was used to evaluate angiogenic marker expression. Recurrence-free survival (RFS), metastasis-free survival (MFS) and disease-specific survival (DSS) were used as endpoints in prognostic impact assessment. Results In univariate analyses, almost all investigated angiogenic markers had prognostic impact in the ET group. In contrast, only FGFR-1 showed any significant prognostic impact in the VR group. In the multivariate analyses, PDGF-D (HR = 1.863, 95% CI = 1.057-3.283, P = 0.031), VEGFR-1 (HR = 2.106, 95% CI = 1.038-4.272, P = 0.039) and VEGF-A (HR 2.095, 95% CI 1.028-4.271, P = 0.042) were independent negative prognosticators for DSS, MFS and RFS, respectively, in the ET group. FGFR-1 was an independent positive prognosticator for DSS (HR = 0.243, 95% CI = 0.095-0.618, P = 0.003) in the VR group. Conclusions Angiogenic molecules from the PDGF and VEGF families have prognostic impact in soft-tissue sarcomas arising in the ET, but not in VR locations. In the latter histological grade and resection margins are the most important prognostic factors.
Collapse
Affiliation(s)
- Thomas K Kilvaer
- Department of Oncology, University Hospital of North Norway, Tromso, 9037 Norway.
| | | | | | | | | | | | | |
Collapse
|
5
|
Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas. BMC Clin Pathol 2013; 13:9. [PMID: 23497154 PMCID: PMC3602168 DOI: 10.1186/1472-6890-13-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2012] [Accepted: 03/08/2013] [Indexed: 12/02/2022] Open
Abstract
Background S-phase kinase-associated protein 2 (Skp2) is a member of mammalian F-box proteins. The purpose of this study is to clarify the prognostic significance of expression of Skp2 related to gender, estrogen receptor (ER) and progesterone receptor (PGR) in soft tissue sarcomas (STS). Skp2 has been demonstrated to display an oncogenic function since its overexpression has been observed in many human cancers. Optimized treatment of STS requires better identification of high-risk patients who will benefit from adjuvant therapy. The prognostic significance of Skp2 related to ER and PGR in STS has not been sufficiently investigated. Methods Tissue microarrays from 193 STS patients were constructed from duplicate cores of viable and representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the expression of Skp2, ER and PGR. Results In univariate analyses, high tumor expression of Skp2 correlated (p = 0.050) with reduced disease-specific survival (DSS). In subgroup analyses expression of PGR in males (p = 0.010) and in patients older than 60 years (p = 0.043) were negative prognostic factors for DSS. Expression of ER in females was a positive prognostic factor for DSS (p = 0.041). In co-expression analyses in the whole cohort, low expression of Skp2 in combination with low expression of ER was positive for DSS (p = 0.049). In females high expression of Skp2 in combination with low expression of ER was a negative prognosticator (p = 0.021). In the multivariate analyses, age (p = 0.012), malignancy grade (p < 0.001), wide resection margins (P = 0.010), ER negative / PGR positive co-expression profile (p = 0.002) and ER positive / PGR negative co-expression profile (p = 0.015) were independent negative prognostic factors for DSS. In females expression of Skp2 (p = 0.006) was associated with shorter DSS. Conclusions We found diverse prognostic impacts of expression of Skp2, ER, PGR and DSS in male and female patients with STS. In men, but not women, ER positive / PGR negative co-expression profile was an independent negative prognostic factor for DSS. In women, but not men, high expression of Skp2 was associated with reduced DSS.
Collapse
Affiliation(s)
- Sveinung W Sorbye
- Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One 2012; 7:e47068. [PMID: 23071715 PMCID: PMC3465267 DOI: 10.1371/journal.pone.0047068] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Accepted: 09/07/2012] [Indexed: 01/12/2023] Open
Abstract
PURPOSE The purpose of this study is to clarify the prognostic significance of expression of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas (STS). Optimised treatment of STS requires better identification of high risk patients who will benefit from adjuvant therapy. The prognostic significance of Jab1, p16, p21, p62, Ki67 and Skp2 in STS has not been sufficiently investigated. EXPERIMENTAL DESIGN Tissue microarrays from 193 STS patients were constructed from duplicate cores of viable and representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the expression of Jab1, p16, p21, p62, Ki67 and Skp2. RESULTS In univariate analyses, high tumor expression of Ki67 (P = 0.007) and Skp2 (P = 0.050) correlated with shorter disease-specific survival (DSS). In subgroup analysis, a correlation between Skp2 and DSS was seen in patients with malignancy grade 1 or 2 (P = 0.027), tumor size >5 cm (P = 0.018), no radiotherapy given (P = 0.029) and no chemotherapy given (P = 0.017). No such relationship was apparent for Jab1, p16, p21 and p62; but p62 showed a positive correlation to malignancy grade (P = 0.019). Ki67 was strongly positively correlated to malignancy grade (P = 0.001). In multivariate analyses, Skp2 was an independent negative prognostic factor for DSS in women (P = 0.009) and in patients without administered chemotherapy or radiotherapy (P = 0.026). CONCLUSIONS Increased expression of Skp2 in patients with soft tissue sarcomas is an independent negative prognostic factor for disease-specific survival in women and in patients not administered chemotherapy or radiotherapy. Besides, further studies are warranted to explore if adjuvant chemotherapy or radiotherapy improve the poor prognosis of STS with high Skp2 expression.
Collapse
Affiliation(s)
- Sveinung W Sorbye
- Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol 2012; 12:7. [PMID: 22554285 PMCID: PMC3408340 DOI: 10.1186/1472-6890-12-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2012] [Accepted: 05/03/2012] [Indexed: 01/22/2023] Open
Abstract
Background Prognostic markers in curable STS may have the potential to guide therapy after surgical resection. The purpose of this study was to clarify the prognostic impact of the presence of cells and growth factors belonging to the innate immune system in soft tissue sarcomas (STS). The significance of macrophages (CD68), their growth factor macrophage colony-stimulating factor (M-CSF), its receptor colony-stimulating factor-1 receptor (CSF-1R), natural killer cells (CD57) and the general immunomodulating molecule (TGF-beta) are all controversial in STS. Herein, these markers are evaluated and compared to the cell proliferation marker Ki67. Methods Tissue microarrays from 249 patients with non-gastrointestinal (non-GIST) STS were constructed from duplicate cores of viable and representative neoplastic tumor areas and duplicate cores of peritumoral capsule. Immunohistochemistry was used to evaluate the expression of CD68, M-CSF, CSF-1R, CD57, TGF-beta and Ki67 in tumor and peritumoral capsule. Results In univariate analyses increased expression of M-CSF (P = 0.034), Ki67 (P < 0.001) and TGF-beta (P = 0.003) in tumor correlated with shorter disease-specific survival (DSS). Increased expression of CD68 in tumor correlated significantly with malignancy grade (P = 0.016), but not DSS (P = 0.270). Increased expression of Ki67 in peritumoral capsule tended to correlate with a shorter DSS (P = 0.057). In multivariate analyses, co-expression of M-CSF and TGF-beta (P = 0.022) in tumor and high expression of Ki67 (P = 0.019) in peritumoral capsule were independent negative prognostic factors for DSS. Conclusions Increased co-expression of M-CSF and TGF-beta in tumor in patients with STS, and increased expression of Ki67 in peritumoral capsule were independent negative prognostic factors for DSS.
Collapse
Affiliation(s)
- Sveinung W Sorbye
- Dept of Clinical Pathology, University Hospital of North Norway, Tromso, 9038, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol 2012; 12:5. [PMID: 22375962 PMCID: PMC3312871 DOI: 10.1186/1472-6890-12-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2011] [Accepted: 02/29/2012] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The purpose of this study was to clarify the prognostic significance of peritumoral lymphocyte infiltration in the capsule of soft tissue sarcomas (STS). Multiple observations in preclinical and clinical studies have shown that the immune system has a role in controlling tumor growth and progression. Prognostic markers in potentially curable STS should guide therapy after surgical resection. The immune status at the time of resection may be important, but the prognostic significance of peritumoral lymphocytes is unknown. METHODS Tissue microarrays from 80 patients with STS were constructed from duplicate cores of tissue from the tumor and the peritumoral capsule. Immunohistochemistry was used to evaluate the CD3+, CD4+, CD8+ and CD20+ lymphocytes in the tumor and the peritumoral capsule. RESULTS In univariate analyses, increasing numbers of CD20+ (P = 0.032) peritumoral lymphocytes were associated with a reduced disease free survival (DSS). In multivariate analyses, a high number of CD20+ peritumoral lymphocytes (P = 0.030) in the capsule was an independent negative prognostic factor for DSS. There were no such associations of lymphocyte infiltration in the tumor. CONCLUSIONS A high density of CD20+ peritumoral lymphocytes is an independent negative prognostic indicator for patients with STS. Further research is needed to determine whether CD20 cells in the peritumoral capsule of STS may promote tumor invasion in the surrounding tissue and increase the metastatic potential.
Collapse
Affiliation(s)
- Sveinung W Sorbye
- Dept of Clinical Pathology, University Hospital of North Norway, 9038 Tromso, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT. The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J Transl Med 2011; 9:200. [PMID: 22107784 PMCID: PMC3254077 DOI: 10.1186/1479-5876-9-200] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2011] [Accepted: 11/22/2011] [Indexed: 01/08/2023] Open
Abstract
Background The PI3K/Akt pathway is involved in cellular survival pathways by inhibiting apoptotic processes and stimulating cell growth and proliferation. Its negative prognostic value has been proven in many types of cancer. In soft tissue sarcomas, the expression profiles of the PI3K/Akt pathway components are poorly defined and their significance uncertain. We aimed to investigate the prognostic impact of Akt (Akt1) phosphorylated at threonine308 and serine473, Akt2, Akt3, PI3K and PTEN, alone and in coexpression with ER and PgR in non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STSs). Patients and methods Tumor samples and clinical data from 249 patients with non-GIST STS were obtained, and tissue microarrays (TMAs) were constructed. Immunohistochemistry (IHC) was used to evaluate marker expression in tumor cells. Results In univariate analyses, the expression levels of p-Akt Thr308 (P = 0.002), Akt2 (P = 0.008) and PI3K (P < 0.001) were significant prognostic factors. In the multivariate analysis, high PI3K expression was an independent negative prognosticator (HR = 1.5, 95% CI = 1.0-2.2, P = 0.042) in addition to advanced age, tumor depth, high malignancy grade, metastasis at diagnosis, surgery and positive resection margins. p-Akt Thr308 expression had strong unfavorable effect in men only (P = 0.009). In contrast, p-Akt Ser473 expression had strong unfavorable impact in women (P = 0.023). PgR-/p-Akt Ser473+ phenotype tended to have less favorable impact in women (P = 0.087), but was the most favorable one in men (P = 0.010). Conclusion Expression of PI3K was significantly associated with aggressive behavior and shorter DSS in non-GIST STSs. The site of Akt phosphorylation seems to have gender-dependent impact on survival in STS patients.
Collapse
Affiliation(s)
- Andrej Valkov
- Dept of Clinical Pathology, University Hospital of Northern Norway, Tromsø, Norway.
| | | | | | | | | | | | | |
Collapse
|
10
|
Kilvaer TK, Valkov A, Sorbye SW, Smeland E, Bremnes RM, Busund LT, Donnem T. Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med 2011; 9:104. [PMID: 21733164 PMCID: PMC3141498 DOI: 10.1186/1479-5876-9-104] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2011] [Accepted: 07/06/2011] [Indexed: 03/29/2023] Open
Abstract
Background Non-gastrointestinal stromal tumor soft-tissue sarcomas (non-GIST STSs) constitute a heterogeneous group of tumors with poor prognosis. Fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor-1 (FGFR-1), in close interplay with platelet-derived growth factor-B (PDGF-B) and vascular endothelial growth factor receptor-3 (VEGFR-3), are strongly involved in angiogenesis. This study investigates the prognostic impact of FGF2 and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors from non-GIST STS patients. Methods Tumor samples from 108 non-GIST STS patients were obtained and tissue microarrays were constructed for each specimen. Immunohistochemistry was used to evaluate the expressions of FGF-2, FGFR-1, PDGF-B and VEGFR-3. Results In the multivariate analysis, high expression of FGF2 (P = 0.024, HR = 2.2, 95% CI 1.1-4.4) and the co-expressions of FGF2 & PDGF-B (overall; P = 0.007, intermediate; P = 0.013, HR = 3.6, 95% CI = 1.3-9.7, high; P = 0.002, HR = 6.0, 95% CI = 2.0-18.1) and FGF2 & VEGFR-3 (overall; P = 0.050, intermediate; P = 0.058, HR = 2.0, 95% CI = 0.98-4.1, high; P = 0.028, HR = 2.6, 95% CI = 1.1-6.0) were significant independent prognostic indicators of poor disease-specific survival. Conclusion FGF2, alone or in co-expression with PDGF-B and VEGFR-3, is a significant independent negative prognosticator in widely resected non-GIST STS patients.
Collapse
Affiliation(s)
- Thomas K Kilvaer
- Institute of Medical Biology, University of Tromso, PB 9037, Tromso, Norway.
| | | | | | | | | | | | | |
Collapse
|
11
|
Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, Busund LT. The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas. PLoS One 2011; 6:e17507. [PMID: 21390241 PMCID: PMC3048407 DOI: 10.1371/journal.pone.0017507] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Accepted: 02/04/2011] [Indexed: 11/19/2022] Open
Abstract
Aims Transforming growth factor-β (TGF-β), fascin, nuclear factor-kappa B (NF-κB) p105, protein-kinase C-zeta (PKC-ζ), partioning-defective protein-6 (Par-6), E-cadherin and vimentin are tumor promoting molecules through mechanisms involved in cell dedifferentiation. In soft tissue sarcomas, their expression profile is poorly defined and their significance is uncertain. We aimed to investigate the prognostic impact of TGF-β1, NF-κB p105, PKC-ζ, Par-6α, E-cadherin and vimentin in non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STSs). Patients and Methods Tumor samples and clinical data from 249 patients with non-GIST STS were obtained, and tissue microarrays (TMAs) were constructed for each specimen. Immunohistochemistry (IHC) was used to evaluate marker expression in tumor cells. Results In univariate analysis, the expression levels of TGF-β1 (P = 0.016), fascin (P = 0.006), NF-κB p105 (P = 0.022) and PKC-ζ, (P = 0.042) were significant indicators for disease specific survival (DSS). In the multivariate analysis, high TGF-β1 expression was an independent negative prognostic factor for DSS (HR = 1.6, 95% CI = 1.1–2.4, P = 0.019) in addition to tumor depth, malignancy grade, metastasis at diagnosis, surgery and positive resection margins. Conclusion Expression of TGF-β1 was significantly associated with aggressive behavior and shorter DSS in non-GIST STSs.
Collapse
Affiliation(s)
- Andrej Valkov
- Department of Clinical Pathology, University Hospital of Northern Norway, Tromsø, Norway.
| | | | | | | | | | | | | |
Collapse
|
12
|
Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T. Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One 2010; 5:e15368. [PMID: 21179485 PMCID: PMC3001883 DOI: 10.1371/journal.pone.0015368] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2010] [Accepted: 11/11/2010] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND In non-gastrointestinal stromal tumor soft tissue sarcoma (non-GIST STS) optimal treatment is surgery with wide resection margins. Vascular endothelial growth factors (VEGFs) and receptors (VEGFRs) are known to be key players in the initiation of angiogenesis and lymphangiogenesis. This study investigates the prognostic impact of VEGFs and VEGFRs in non-GIST STS with wide and non-wide resection margins. METHODS Tumor samples from 249 patients with non-GIST STS were obtained and tissue microarrays were constructed for each specimen. Immunohistochemistry was used to evaluate the expressions of VEGF-A, -C and -D and VEGFR-1, -2 and -3. RESULTS In the univariate analyses, VEGF-A (P=0.040) in the total material, and VEGF-A (P=0.018), VEGF-C (P=0.025) and VEGFR-3 (P=0.027) in the subgroup with wide resection margins, were significant negative prognostic indicators of disease-specific survival (DSS). In the multivariate analysis, high expression of VEGFR-3 (P=0.042, HR=1.907, 95% CI 1.024-3.549) was an independent significant negative prognostic marker for DSS among patients with wide resection margins. CONCLUSION VEGFR-3 is a strong and independent negative prognostic marker for non-GIST STSs with wide resection margins.
Collapse
Affiliation(s)
| | - Andrej Valkov
- Institute of Medical Biology, University of Tromso, Tromso, Norway
- Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway
| | - Sveinung Sorbye
- Institute of Medical Biology, University of Tromso, Tromso, Norway
- Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway
| | - Eivind Smeland
- Department of Oncology, University Hospital of North Norway, Tromso, Norway
| | - Roy M. Bremnes
- Department of Oncology, University Hospital of North Norway, Tromso, Norway
- Institute of Clinical Medicine, University of Tromso, Tromso, Norway
| | - Lill-Tove Busund
- Institute of Medical Biology, University of Tromso, Tromso, Norway
- Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway
| | - Tom Donnem
- Department of Oncology, University Hospital of North Norway, Tromso, Norway
- Institute of Clinical Medicine, University of Tromso, Tromso, Norway
- * E-mail:
| |
Collapse
|
13
|
Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G. High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant 2001; 28:849-57. [PMID: 11781645 PMCID: PMC7091626 DOI: 10.1038/sj.bmt.1703244] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2001] [Accepted: 07/16/2001] [Indexed: 12/29/2022]
Abstract
Register data suggest that patients with Hodgkin's disease (HD) given high-dose therapy (HDT) with peripheral blood progenitor cells (PBPC) have a less favourable prognosis as compared to those given bone marrow as stem cell support. Since this can be due to infusion of tumour cells contaminating the PBPC grafts, we initiated a feasibility study in which PBPC grafts from HD patients were purged by CD34(+) cell enrichment. Controversy exists about whether the use of CD34(+) enriched stem cells leads to a delayed haematological and immune reconstitution. We compared these parameters, including risk of infections and clinical outcome after HDT, in patients with HD given either selected CD34(+) cells or unmanipulated PBPC as stem cell support. From October 1994 to May 2000, 40 HD patients with primary refractory disease or relapse were treated with HDT and supported with either selected CD34(+) cells (n = 21) or unmanipulated PBPC (n = 19) as stem cell support. All patients had chemosensitive disease at the time of transplantation. A median of 5.8 (range 2.7-20.0) vs 4.5 (range 2.3-17.6) x 10(6) CD34(+) cells per kilo were reinfused in the CD34(+) group and PBPC group, respectively. No difference was observed between the two groups with regard to time to haematological engraftment, reconstitution of B cells, CD56(+) cells and T cells at 3 and 12 months and infectious episodes after HDT. Two (5%) treatment-related deaths, one in each group, were observed. The overall survival at 4 years was 86% for the CD34(+)group and 74% for the PBPC group with a median follow-up of 37 months (range 1-61) and 46 months (range 4-82), respectively (P = 0.9). The results of this study demonstrate that the use of CD34(+) cells is safe and has no adverse effects either with respect to haematological, immune reconstitution or to infections after HDT.
Collapse
Affiliation(s)
- A K Blystad
- Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway
| | | | | | | | | | | |
Collapse
|
14
|
Smeland E. [University function at the central hospital in Akershus]. Tidsskr Nor Laegeforen 1999; 119:1647. [PMID: 10385812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
|
15
|
Ly B, Hammerstrøm J, Bergheim J, Dahl IM, Grøttum KA, Lødemel B, Baklien K, Smeland E. [Chronic lymphatic leukemia. Immunophenotyping as an aid to correct diagnosis]. Tidsskr Nor Laegeforen 1998; 118:233-7. [PMID: 9485618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The purpose of the study was to examine the validity of the primary diagnosis in chronic lymphocytic leukemia based on clinical and morphological criteria, and to examine the role of immune phenotyping for correct diagnosis in an unselected population-based group of patients. Over a 2-year period leukemic cells from 222 of 235 patients in Norway with a recent clinical diagnosis of chronic lymphocytic leukemia (CLL) were immune phenotyped in order to find cases erroneously diagnosed as CLL. Median age was 72.5 years, and the ratio of men to women was 1.47. At the time of diagnosis, 77% of the patients were in Binet stage A and 23% in stage B or C. Immune phenotyping, in some patients followed by lymph node or bone marrow biopsy, showed a different diagnosis in 11 (5%) of 222 patients: prolymphocytic leukemia, four patients (three B-cell and one T-cell); morbus Waldenstrøm, one patient; T-cell CLL, one patient; hairy cell leukemia, one patient; mycosis fungoides, one patient; mantle cell lymphoma, one patient; monocytoid B-cell lymphoma, one patient and immunoblastic lymphoma one patient. In eight of these 11 patients, the clinical features or morphology, or both, were atypical for CLL, but this was not recognized at the time of diagnosis. Thus, immune phenotyping is valuable for correct diagnosis in a small subgroup of patients with chronic B- or T-cell leukemia, and it is essential in patients with modest lymphocytosis (lymphocytes < 10. 10(9)/1).
Collapse
MESH Headings
- Adult
- Aged
- Diagnosis, Differential
- Female
- Humans
- Immunophenotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Prolymphocytic/diagnosis
- Leukemia, Prolymphocytic/immunology
- Leukemia, Prolymphocytic, T-Cell/diagnosis
- Leukemia, Prolymphocytic, T-Cell/immunology
- Lymphocytosis/diagnosis
- Lymphocytosis/immunology
- Male
- Middle Aged
Collapse
Affiliation(s)
- B Ly
- Hematologisk avdeling, Medisinsk klinikk Aker sykehus Oslo
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Smeland E. [Changing physician's role]. Tidsskr Nor Laegeforen 1997; 117:4290. [PMID: 9441481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
17
|
Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O. Purging of tumor cells from leukapheresis products: experimental and clinical aspects. J Hematother 1996; 5:427-36. [PMID: 8877718 DOI: 10.1089/scd.1.1996.5.427] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Peripheral blood progenitor cell autografts are being used increasingly in conjunction with high-dose therapy of cancer patients, in the belief that these products have a low probability of containing tumor cells. However, recent findings demonstrate that tumor cell involvement is frequent in leukapheresis products. Although the clinical value of purging has not been clinically established by prospective randomized trials, several studies indicate that contaminating tumor cells in autografts contribute to relapse of the disease in the recipients. We describe our experimental and clinical experience in purging tumor cells from leukapheresis products. Based on our work with purging of lymphoma cells from bone marrow by the use of anti-B cell and anti-T cell antibodies and immunobeads, a purging procedure to deplete leukapheresis products of lymphoma cells has been developed. Moreover, we present data showing that breast cancer cells can be efficiently removed from leukapheresis products using antibreast cancer antibodies, either in combination with immunobeads or as immunotoxins. Our experience with enrichment of CD34 cells employing immunobeads in leukaphresis products from patients with breast cancer and lymphomas shows high purity and yield of CD34 cells. In spite of this, contaminating tumor cells can be observed, strongly suggesting that a combination of CD34 cell enrichment and a purging procedure might be warranted.
Collapse
Affiliation(s)
- G Kvalheim
- Department of Radiotherapy and Oncology, Norwegian Radium Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Røsok O, Odeberg J, Rode M, Stokke T, Funderud S, Smeland E, Lundeberg J. Solid-phase method for differential display of genes expressed in hematopoietic stem cells. Biotechniques 1996; 21:114-21. [PMID: 8816245 DOI: 10.2144/96211rr02] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
A solid-phase differential display method was designed to analyze differential gene expression in samples with low amounts of mRNA. The principle was based on using a biotinylated probe to capture the mRNA and priming both the first-strand synthesis and the subsequent polymerase chain reaction step. Coupling the mRNA to a solid phase during the procedure simplified the purification steps, limited sample loss and enabled rapid handling of mRNA. DNA contamination was also minimized when the mRNA was bound to a solid phase. Optimization of the differential display method was achieved by analyzing both the enzymatic conditions and the required cell amounts. The approach was used for the characterization of genes expressed in the most immature hematopoietic progenitor cells (CD34+CD38-). The majority of the differentially expressed fragments represented previously uncharacterized sequences.
Collapse
Affiliation(s)
- O Røsok
- Norwegian Radium Hospital, Oslo, Norway
| | | | | | | | | | | | | |
Collapse
|
19
|
Smeland E, Fuskevåg OM, Nymann K, Svendesn JS, Olsen R, Lindal S, Bremnes RM, Aarbakke J. High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 1996; 37:415-22. [PMID: 8599863 DOI: 10.1007/s002800050406] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
To elucidate mechanisms for methotrexate (MTX)-induced renal and hepatic toxicity, we investigated the acute effects of bolus plus continuous infusion of up to 0.4 g/kg 7-hydroxymethotrexate (7-OH-MTX) in the rat. We demonstrate for the first time in any species the occurrence of acute lethal toxicity within a few hours after 7-OH-MTX administration. Serum concentrations of 7-OH-MTX measured at the time of death were 1.4 mM (mean), about one-half of those achieved in some patients after infusion of high-dose MTX (HD-MTX) in the clinic. The data suggest an approximate LD50 (the dose lethal to 50% of the study population) of 0.3 g/kg and a steep dose/lethality curve for 7-OH-MTX. Moreover, acute renal and hepatic toxicity occurred as evidenced by severe morphological findings and increased serum levels of creatinine and liver transaminases. In all rats subjected to continuous infusion of 7-OH-MTX, yellow microscopic precipitations were apparent in the kidney tubules. Crystallization was also seen in bile ducts of the liver in some of the rats. These results further support that the formation of 7-OH-MTX is disadvantageous and that reported attempts to prevent its formation during MTX treatment are warranted.
Collapse
Affiliation(s)
- E Smeland
- Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Norway
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Smeland E. [Physicians liable for military service for sale]. Tidsskr Nor Laegeforen 1995; 115:3072. [PMID: 7570542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
|
21
|
Smeland E, Bremnes RM, Fuskevag OM, Aarbakke J. The effect of calcium channel blockers and calcium on methotrexate accumulation in rat hepatocytes. Anticancer Res 1995; 15:1221-5. [PMID: 7654001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The effects of diltiazem (DIL), verapamil (VRP) and Ca2+ on the accumulation of methotrexate (MTX) were investigated in isolated rat hepatocytes. At the physiological 2 mM Ca2+, the calcium-channel blockers DIL (100 microM) and VRP (50 microM) significantly reduced the hepatocellular accumulation of MTX. By increasing the Ca2+ concentration to 7 mM control MTX levels (at 2 mM Ca2+) were restored with VRP, and resulted in MTX levels above the controls for DIL. Ca2+ at 7 mM significantly enhanced MTX accumulation in the hepatocyte suspensions after 60 min. The concentration time curves for MTX indicated that for the first 10 min influx was the dominating process. Dixon plot analysis of this uptake phase revealed Ki values of 140 microM for DIL and 75 microM for VRP. The data suggested that DIL was a non-competitive, and VRP a competitive inhibitor of MTX influx. Hence, the inhibitory effect on MTX accumulation mediated by DIL and VRP could be due to different mechanisms.
Collapse
Affiliation(s)
- E Smeland
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | |
Collapse
|
22
|
Deggerdal AH, Pettersen F, Kvalheim G, Hornes E, Smeland E, Fodstad O, Hovig E. Semiquantitative polymerase chain reaction for t(14;18) in follicular lymphomas: a colorimetric approach. J Transl Med 1995; 72:411-8. [PMID: 7723279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND Autologous bone marrow transplantation is increasingly being used in the management of several types of cancer, and to avoid reintroduction of malignant cells, bone marrow purging is often performed. In such cases, sensitive quantitation methods are needed both to assess the efficacy of the purging and for surveillance of patients in remission. Polymerase chain reaction (PCR) has the necessary sensitivity for this application, but it requires that the cancer cells can be recognized by a defined genetic abnormality. In addition, PCR is in principle a qualitative technique and must be modified for quantitative purposes. In follicular non-Hodgkin's lymphomas, the translocation t(14;18) (q32;q21) is common and is used here for model experiments. EXPERIMENTAL DESIGN A PCR-based method for the quantitation of translocation-positive cells was developed on the basis of coamplification of cancer-specific target molecules with competitor molecules of known concentration. Gel electrophoresis was substituted by a colorimetric quantitation system to cope with patient PCR products of the same size as the competitor product and ease automation of the method at a later stage. Cell line Karpas 422, which contains the t(14;18) (q32;21) translocation, was used to validate the method. The method was used to assess the efficacy of a patient bone marrow purging where the initial infiltration levels were too low for traditional detection systems. RESULTS A reproducible and near linear response was obtained between 70 pg and 200 ng K422 DNA, equivalent to 10 K422 cells and 30,000 K422 cells, respectively. Bone marrow infiltration in one patient was 0.6 to 0.7% before malignant cell removal and 3 to 7 x 10(-4) after removal. The corresponding figures for the other patient were 2% and 3 to 7 x 10(-4), respectively. CONCLUSIONS The method presented has a sufficient dynamic range for applications like evaluation of bone marrow purging or monitoring of minimal residual disease. Adaptation of this method to other translocations is discussed.
Collapse
Affiliation(s)
- A H Deggerdal
- Department of Immunology, Norwegian Radium Hospital, Oslo
| | | | | | | | | | | | | |
Collapse
|
23
|
Aas-Eng DA, Asheim HC, Deggerdal A, Smeland E, Funderud S. Characterization of a promoter region supporting transcription of a novel human beta-galactoside alpha-2,6-sialyltransferase transcript in HepG2 cells. Biochim Biophys Acta 1995; 1261:166-9. [PMID: 7893756 DOI: 10.1016/0167-4781(94)00250-7] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In humans, two transcripts encoding beta-galactoside alpha-2,6-sialytransferase (EC 2.4.99.1.) have previously been described. One of the transcripts is widely expressed, whereas the other is restricted to mature B-cells. In this study we demonstrate the existence of a third transcript in the hepatoma cell-line HepG2. The expression of this transcript is controlled by a promoter region which efficiently supports transcription in HepG2 cells, and which harbours putative binding sites for liver-enriched and acute phase inducible transcription factors.
Collapse
Affiliation(s)
- D A Aas-Eng
- Department of Immunology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo
| | | | | | | | | |
Collapse
|
24
|
Smeland E, Bremnes RM, Fuskevåg OM, Aarbakke J. Perturbation of methotrexate transport by verapamil, vinblastine, taurocholate and bromosulfophthalein in rat hepatocytes. Anticancer Res 1995; 15:45-50. [PMID: 7733639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND Methotrexate (MTX) is extensively used in different combination chemotherapy regimens. More knowledge about interactions and their mechanisms in target cancer cells and normal cells is needed to improve therapeutic efficacy and reduce toxicity. MATERIALS AND METHODS The effect of verapamil (VRP), vinblastine (VBL), taurocholate (TAURO) and bromosulfophthalein (BSP) on MTX transport were studied in freshly isolated rat hepatocytes. RESULTS During 60 min, 50 microM VRP decreased the hepatocellular MTX accumulation with 29%; whereas 100 microM BSP reduced MTX entrance with 15%. 100 microM VBL and 100 microM TAURO reduced the intracellular accumulation of MTX with 36% and 23%, respectively. VRP and BSP appeared to be selective MTX influx blockers, whereas VBL and TAURO inhibited both MTX influx and efflux, however, with major inhibition on MTX influx. Dixon plot analyses for TAURO and BSP were suggestive of competitive inhibition, giving inhibition constants (Ki) values of 105 microM for TAURO, and 800 microM for BSP. CONCLUSION The data demonstrate for the first time a selective inhibitory effect of VRP upon MTX influx in isolated rat hepatocytes, whereas BSP, a potent MTX efflux inhibitor in malignant cells fails to achieve this effect in the normal cell type here investigated.
Collapse
Affiliation(s)
- E Smeland
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | |
Collapse
|
25
|
Smeland E, Bremnes RM, Andersen A, Jaeger R, Eide TJ, Huseby NE, Aarbakke J. Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemother Pharmacol 1994; 34:119-24. [PMID: 8194163 DOI: 10.1007/bf00685928] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
To examine directly the hepatic and renal toxicity of 7-hydroxymethotrexate (7-OH-MTX) without interference of the parent compound methotrexate (MTX), we purified and gave 100 mg/kg 7-OH-MTX to rats, a dose resulting in serum levels of 7-OH-MTX comparable with those achieved in the clinic after the administration of high-dose MTX (HD-MTX). After only 5 h, the 7-OH-MTX-treated rats demonstrated 2.6-fold increases in serum creatinine values and 2-fold elevations in serum aspartate aminotransferase (ASAT) levels as compared with the controls. Morphologic evidence of toxicity, however, was apparent only in the kidneys. Intraluminal cellular debris containing membranous material and deteriorated organelles was seen, but no precipitate of the delivered drug. The peak serum concentration of 7-OH was up to 939 microM, and concentrations of 7-OH-MTX declined triphasically, showing a t1/2 alpha value of 2.45 min, a t1/2 beta value of 30.5 min, and a terminal half-life (t1/2 gamma) of 240 min. The total clearance value was 14.5 ml min-1 kg, and the postdistributional volume of distribution (V beta) was 5070 ml/kg. Our results may indicate a direct toxic effect of 7-OH-MTX on kidney and liver cells.
Collapse
Affiliation(s)
- E Smeland
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | | | | | | | |
Collapse
|
26
|
Bremnes R, Smeland E, Aarbakke J. Interactions of vinca alkaloids with hepato-cellular methotrexate transport. Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91291-r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Smeland E, Bremnes RM, Bessesen A, Jaeger R, Aarbakke J. Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes. Cancer Chemother Pharmacol 1993; 32:209-14. [PMID: 8500226 DOI: 10.1007/bf00685837] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The accumulation of methotrexate (MTX) in the presence of vinblastine (VBL) and vincristine (VCR) was studied in isolated rat hepatocytes. In accordance with our recent study on vindesine (VDS), we found VBL and VCR to reduce net MTX accumulation significantly at 15 min after MTX addition. Drug concentrations of 100 microM VBL and 500 microM VCR led to 67% and 82% reductions in intracellular MTX, respectively. Since there was only a slight inhibition of MTX efflux by 100 microM VBL, the accumulation data demonstrate that the major effect of VBL is on MTX influx. Dixon-plot analyses are suggestive of competitive inhibition of the MTX influx, yielding inhibition constants (Ki values) of 55 microM for VBL and 110 microM for VCR. Since the Ki values correspond grossly to plasma levels obtained in humans shortly after the infusion of therapeutic doses of the vinca alkaloids studied herein, the interaction with MTX uptake could serve to diminish the toxicity of MTX to nonmalignant cells.
Collapse
Affiliation(s)
- E Smeland
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | | | |
Collapse
|
28
|
Abstract
The effect of vindesine (VDS) on methotrexate (MTX) disposition was studied in bile-drained rats administered VDS prior to [3H]MTX, and in isolated rat hepatocytes and rat liver homogenate concomitantly incubated with MTX and VDS at 37 degrees. In vivo, 7-hydroxylation was reduced by 0.65 mg/kg VDS. In VDS-treated animals, biliary recovery of the MTX dose (50 mg/kg) as 7-hydroxymethotrexate (7-OH-MTX) (1.75 +/- 0.2%, mean +/- SEM) was significantly reduced compared to controls (2.83 +/- 0.57%). In vitro, hydroxylation of MTX (10-200 microM) in hepatocytes was reduced by 14.3 and 66.4% (means) at 12.5 and 100 microM VDS, respectively. With increasing VDS concentrations up to 100 microM, a reduction in intracellular MTX accumulation could account for the decreased MTX hydroxylation. Experiments in a cell free system gave no evidence of inhibition of 7-OH-MTX formation by VDS. In vitro MTX transport studies demonstrated that VDS inhibited the hepatocellular influx of MTX, as (1) the accumulation of MTX corresponded inversely to increasing VDS concentrations and (2) the MTX efflux was not increased by VDS. The apparent Ki for VDS inhibition of MTX influx was 57 microM. We suggest that VDS, by reducing the 7-OH-MTX formation in liver cells, may have implications for combination chemotherapy regimens which include MTX.
Collapse
Affiliation(s)
- R M Bremnes
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | | | |
Collapse
|
29
|
Abstract
Acute hepatotoxicity after administration of 10-1000 mg/kg methotrexate (MTX) to rats was studied by monitoring serum transaminases, liver morphology, and disposition kinetics of MTX and 7-hydroxy-methotrexate (7-OH-MTX). Half the control rats and rats administered 1000 mg/kg MTX, had their bile duct cannulated. One to 2 hr after administration of 1000 mg/kg MTX, 50% of MTX treated bile-drained rats (Ebc) developed cholestasis despite similar or larger initial bile flow rates than those which did not develop cholestasis (Ebn, controls). In Ebc animals, peak serum ASAT and ALAT levels were 6- and 4-fold higher than that of the control rats, and morphologically, prominent hepatocytic changes and grossly dilated bile canaliculi were found. Immediately prior to cholestasis, the Ebc animals reached biliary 7-OH-MTX levels (8.3 +/- 1.3 mM, mean +/- S.E.M.) which were equivalent to the threshold level for precipitation of 7-OH-MTX in rat bile in vitro, and 3-fold higher than the corresponding levels of 7-OH-MTX in the bile of Ebn rats. Ninety-five % of the drug in the precipitated material was 7-OH-MTX. Hence, 7-OH-MTX may play a role in acute MTX hepatotoxicity, a dose-limiting toxicity that may not be counteracted by leukovorin rescue.
Collapse
Affiliation(s)
- R M Bremnes
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | | | |
Collapse
|
30
|
Abstract
The present study describes the immunomagnetic isolation of human natural killer (NK) and lymphokine activated killer (LAK) cells. Antibodies against CD56 and sheep anti-mouse IgG-coated magnetic monodisperse particles (Dynabeads M-450) were used for the positive isolation of CD56+ cells from unstimulated mononuclear cells (PBMC). A highly enriched population of CD56+ cells (less than or equal to 3% contaminating cells) was obtained with this method. The cellular yield of CD56+ cells was high (5.3% of the unseparated PBMC). The CD56+ cells remained unactivated after separation and preserved their functional characteristics, as measured by cytotoxic activity against the NK sensitive K562 cells. Incubating the CD56+ cells with IL-2 resulted in high LAK activity, as measured by cytotoxic activity against Daudi cells. Large numbers of functionally active CD56+ cells were obtained from IL-2 stimulated lymphocytes using anti-CD56 coated Dynabeads 450. A further enrichment of effector cells with LAK activity was accomplished by depleting the CD56+ cells for T-cells by anti-CD3 coated Dynabeads M450. The immunomagnetic isolation technique described was easy to perform, did not require expensive equipment and yielded NK and LAK cells of satisfactory purity.
Collapse
Affiliation(s)
- B Naume
- Institute of Cancer Research, University of Trondheim, Norway
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
The inhibition of methotrexate (MTX) biotransformation to 7-hydroxymethotrexate (7-OH-MTX) by 4'-(9-acridinylamino)-methanesulfon-m-anisidide (mAMSA) was studied in bile-drained rats in vivo and in incubates of isolated rat hepatocytes and rat-liver homogenate in vitro. In vivo, i.v. administration of 10 mg/kg mAMSA prior to [3H]-MTX infusion (50 mg/kg) led to a significant alteration in 7-OH-MTX kinetics. 7-OH-MTX peak concentrations and AUC in bile and serum were reduced by 75% and the recovery of MTX as 7-OH-MTX in bile and urine decreased by 70%, whereas MTX pharmacokinetics remained unaltered. In suspensions of isolated hepatocytes, 10 microM mAMSA led to a 54% decrease in 7-OH-MTX formation. However, the hepatocellular influx and efflux of MTX was not perturbed by mAMSA. Preincubation of rat-liver homogenates with 1.25-10 microM mAMSA reduced the formation of 7-OH-MTX by up to 73%. mAMSA appeared to inhibit MTX hydroxylation competitively, exhibiting a Ki of 3 microM. Due to its inhibition of the MTX-oxidizing system, mAMSA may be beneficial in combination chemotherapy with MTX by reducing 7-OH-MTX-associated toxicity and, possibly, enhancing the cytotoxic effects of MTX.
Collapse
Affiliation(s)
- R M Bremnes
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | | | |
Collapse
|
32
|
Børresen AL, Brøgger A, Møller P, Smeland E. [Gene technology in the prevention of cancer]. Tidsskr Nor Laegeforen 1989; 109:3430-4. [PMID: 2609305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Cancer may develop in connection with rare, genetic diseases or after exceptional, environmental exposures. Most commonly, however, cancer results from an unhappy coincidence of normal, genetic factors and ordinary, environmental conditions. Oncogenes are normal growth genes. Anti-oncogenes are normal regulatory genes which control growth genes. Cancer may result from changes (mutations) in an oncogene (such as in the Philadelphia chromosome), or from the lack of control of normal oncogenes. The latter may be due to loss of function of a suppressor gene (mutation in an anti-oncogene, such as in retinoblastoma) or through a change in the position of an oncogene (such as in Burkitt's lymphoma and in certain leukemias).
Collapse
|
33
|
Holte H, Stokke T, Smeland E, Watt R, Blomhoff HK, Kaalhus O, Ohlsson R. Levels of myc protein, as analyzed by flow cytometry, correlate with cell growth potential in malignant B-cell lymphomas. Int J Cancer 1989; 43:164-70. [PMID: 2642893 DOI: 10.1002/ijc.2910430130] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
We have analyzed c-myc protein expression during the cell cycle in malignant B-cell lymphomas by dual flow cytometric detection of a fluoresceinated polyclonal anti-myc antibody and propidium iodide which binds stochiometrically to DNA. The data obtained were correlated to other parameters of cell activation such as histopathological grading, expression of the activation antigen 4F2, light scatter (proportional to cellular volume), DNA synthesis and percentage of S-phase cells. The c-myc protein level was strongly correlated to parameters of DNA synthesis/content. In addition, the oncoprotein level was largely unvarying from the late G1 phase through the rest of the cell cycle in both malignant cells and normal purified B cells stimulated to proliferate in vitro.
Collapse
Affiliation(s)
- H Holte
- Department of Pathology, Norwegian Cancer Hospital, Oslo
| | | | | | | | | | | | | |
Collapse
|
34
|
Wathne KO, Norum KR, Smeland E, Blomhoff R. Retinol bound to physiological carrier molecules regulates growth and differentiation of myeloid leukemic cells. J Biol Chem 1988; 263:8691-5. [PMID: 3163997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
We have tested effects of retinol bound to its physiological carrier molecules, i.e. low density lipoprotein chylomicron remnants, and retinol binding protein (RBP) on differentiation and proliferation of myeloid leukemic cells in concentrations that can be obtained in vivo. Data presented in this study show that physiological concentrations of retinyl ester in chylomicron remnants induce differentiation and inhibit proliferation of the cell line HL-60 and promyelocytic leukemic cells in primary culture. Retinyl ester in low density lipoprotein showed no effect either on cell differentiation or proliferation of any of the myeloid cells tested. Retinol bound to RBP induced differentiation of HL-60 cells only in concentrations above those that can be found in vivo. However, cell proliferation was reduced both in HL-60 cells and in primary culture of leukemic cells using physiological concentrations of holo-RBP. These results suggest that retinyl ester in chylomicron remnants is the most effective vehicle for transport of retinol into leukemic cells in vivo.
Collapse
Affiliation(s)
- K O Wathne
- Institute for Nutrition Research, School of Medicine, University of Oslo, Norway
| | | | | | | |
Collapse
|
35
|
Blomhoff HK, Smeland E, Mustafa AS, Godal T, Ohlsson R. Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage. Eur J Immunol 1987; 17:299-301. [PMID: 3030769 DOI: 10.1002/eji.1830170224] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The functional performance of the transforming growth factor beta (TGF beta), appears to depend on the target cell phenotype as well as in vitro culture conditions. We show here that Epstein-Barr virus (EBV)-infection may induce a change in responsiveness to TGF beta, since TGF beta inhibits traverse of the cell cycle of activated normal human B cells, but promotes cell proliferation of EBV-positive Burkitt's lymphoma cell lines as well as EBV-infected B cells. We present evidence that the switch in the responsiveness to TGF beta is mediated by EBV infection, irrespective of the proliferative status of target cells, and thus may contribute to the initiation as well as the maintenance of certain B cell neoplasias.
Collapse
|
36
|
Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenaes O. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986; 293:1195-9. [PMID: 3096429 PMCID: PMC1341978 DOI: 10.1136/bmj.293.6556.1195] [Citation(s) in RCA: 261] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Forty five insulin dependent diabetics were randomised to treatment with continuous subcutaneous insulin infusion (CSII), multiple insulin injections (five or six daily), or conventional twice daily insulin injections. Near normoglycaemia was obtained with CSII and multiple injections but not with conventional treatment (p less than 0.01). Hypoglycaemic coma was observed less frequently with CSII than with multiple injections and conventional treatment (p less than 0.001), but blood glucose concentrations below 2.5 mmol/l (45 mg/100 ml) were more common. After two years fewer retinal microaneurysms and haemorrhages had developed in the patients given CSII and multiple injections compared with those given conventional treatment, in whom the number had increased significantly (p less than 0.01). Motor nerve conduction velocity deteriorated in the patients given conventional treatment; in those given CSII it was unchanged during the first year but had improved after two years (p less than 0.01). Glomerular hyperfiltration was reduced with CSII, but no change occurred in urine albumin excretion rates. Long term near normoglycaemia may prevent the progression of early stages of late diabetic complications.
Collapse
|
37
|
Lea T, Smeland E, Funderud S, Vartdal F, Davies C, Beiske K, Ugelstad J. Characterization of human mononuclear cells after positive selection with immunomagnetic particles. Scand J Immunol 1986; 23:509-19. [PMID: 2422741 DOI: 10.1111/j.1365-3083.1986.tb03083.x] [Citation(s) in RCA: 78] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We have investigated the possibility to employing magnetic monodisperse polymer particles for positive selection of human peripheral blood mononuclear cell populations. By carefully titrating the ratio between particles and cells we succeeded in isolating a number of cell populations that could be cultivated subsequently in vitro for functional studies. The success of the procedure is partly dependent on the properties of the monoclonal antibodies used to sensitize the cells. Provided these antibodies do not react with membrane structures involved in the transduction of activating signals, highly purified, quiescent cell populations can be recovered in a single fractionation step. In most instances particles will detach from the isolated cells by overnight culture, and the particles can then be removed from the system by a suitable magnet. T lymphocytes, subpopulations of T lymphocytes, and B lymphocytes have been isolated in this way and studied in a variety of functional assay systems. Comparison with cells obtained after negative selection clearly demonstrates the usefulness of this technique, especially if the membrane marker selected for it is not directly engaged in the activation processes.
Collapse
|
38
|
Smeland E, Godal T, Ruud E, Beiske K, Funderud S, Clark EA, Pfeifer-Ohlsson S, Ohlsson R. The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. Proc Natl Acad Sci U S A 1985; 82:6255-9. [PMID: 3929253 PMCID: PMC391031 DOI: 10.1073/pnas.82.18.6255] [Citation(s) in RCA: 75] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Resting human B cells can be activated to proliferate in the presence of both polyclonal antibodies to immunoglobulin mu heavy chains and B-cell growth factor (BCGF). This process appears to be temporally controlled in that the initial activation of the B cells and their responsiveness to BCGF is carried out by polyclonal anti-mu-chain antibodies alone. We have used this system to investigate the role of the c-myc gene in the cell cycle of normal human peripheral blood B cells. Our results show that the polyclonal anti-mu-chain antibody-induced B-cell activation is accompanied by a specific induction of c-myc gene expression without promoting subsequent entry into the S phase unless BCGF is added. Monoclonal antibodies to either mu chain or the pan-B-cell antigen Bp35 also revealed a similar G0-to-G1 transition and activation of c-myc gene expression. However, unlike activation with polyclonal anti-mu-chain antibodies, cells stimulated with these monoclonal antibodies do not acquire responsiveness to BCGF. The results imply that additional inducible functions must be present to potentiate the myc-specific function in order for the B cells to acquire the capacity to proliferate in response to BCGF. These findings are discussed in relation to the origin of B-cell malignancies.
Collapse
|
39
|
Heikkilä R, Iversen JG, Smeland E, Godal T. Intracellular Ca2+ buffering potentiates an 86Rb+ permeability response in human lymphocytes. Acta Physiol Scand 1985; 124:247-51. [PMID: 3925725 DOI: 10.1111/j.1748-1716.1985.tb07658.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The effects of antibodies against immunoglobulin delta-heavy chains (anti-delta) on intracellular free Ca2+ concentrations, [Ca2+]i, and 86Rb+ influx in human neoplastic B-cells were tested in vitro. When preloading the cells with high concentrations of the fluorescent Ca2+ chelator quin 2 and subsequently stimulating in EGTA medium, the anti-delta induced rise in [Ca2+]i was strongly reduced or blocked. Nevertheless, 86Rb+ influx, also induced by anti-delta, was potentiated. In fact, in a population of cells in which anti-delta increased [Ca2+]i, but not 86Rb+ influx under standard conditions, the combination of quin-2 preloading and subsequent extracellular Ca2+ chelation by EGTA revealed an anti-delta induced 86Rb+ influx. Most of this influx was ouabain resistant, suggesting only a minor contribution from the Na+/K+ pump. Based on the Ca2+ buffer effect of quin 2 we suggest that the Ca2+ effect on 86Rb+ (K+ analogue) permeability is not mediated by increased [Ca2+]i but rather by the Ca2+ release per se from the plasma membrane.
Collapse
|
40
|
Smeland E, Funderud S, Ruud E, Kiil Blomhoff H, Godal T. Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor. Scand J Immunol 1985; 21:205-14. [PMID: 3887557 DOI: 10.1111/j.1365-3083.1985.tb01422.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We describe two monoclonal antibodies, HH1 and HH2. Both reacted selectively with surface immunoglobulin (sIg)-positive human B cells. Both antibodies stained on average 7-8% of peripheral blood mononuclear cells. They have not been found to react with cells or cell lines of other haematopoietic cell lineages, except that HH2 was positive on a small percentage of cells of the erythroid cell line K562. The molecular weight of the HH1 antigen was 95 kD, as established by Western blotting. Neither of these two antibodies reacted with Ig determinants, Fc receptors, complement receptors, or known class-I or class-II molecules. A combination of these antibodies was used in a direct panning technique for high-yield enrichment of normal B lymphocytes from peripheral blood. The enriched B cells could be further purified by lysis of T cells (final yield, on average 72 +/- 8% of initial B cells) or by a second panning (yield, 35 +/- 11%). The purified B cells contained less than 1% contaminating T cells and less than 0.5% monocytes and were used in an assay for B-cell-stimulating factor which they showed a normal and very reproducible proliferative response.
Collapse
|